Overview

A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

Status:
Recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the long-term safety of nemolizumab (CD14152) in participants with prurigo nodularis (PN).
Phase:
Phase 3
Details
Lead Sponsor:
Galderma R&D